Aclarion Announces Statistically Significant Nociscan Cost-Effectiveness Abstract Presented at ISASS Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Aclarion announced that their Nociscan cost-effectiveness abstract was presented at the ISASS Annual Meeting, showing that Nociscan statistically dominates provocative discography (PD) in terms of cost and effectiveness. The study was performed at CDMI through an NSF grant sponsored by Aclarion.
June 08, 2023 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclarion's Nociscan cost-effectiveness abstract presentation at ISASS demonstrates its superiority over provocative discography, potentially boosting the company's market position.
The presentation of the Nociscan cost-effectiveness abstract at the ISASS Annual Meeting highlights its advantages over provocative discography in terms of cost and effectiveness. This positive news could potentially boost Aclarion's market position and attract more customers, leading to a positive short-term impact on ACON's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100